MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Safety, Pharmacokinetics and Pharmacodynamics of BIBR 1048 MS Capsule in Healthy Male Subjects of Japanese and Caucasian Origin

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BIBR 1048 MS low dose
Drug: BIBR 1048 MS medium dose
Drug: BIBR 1048 MS high dose
First Posted Date
2014-06-23
Last Posted Date
2018-08-31
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
42
Registration Number
NCT02170909

BIBR 1048 in the Prevention of Venous Thromboembolism in Patients Undergoing Primary Elective Total Hip Replacement Surgery

Phase 2
Completed
Conditions
Venous Thromboembolism
Interventions
First Posted Date
2014-06-23
Last Posted Date
2018-08-31
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
289
Registration Number
NCT02170701

Bioavailability of BIBR 1048 MS Tablets in Healthy Subjects With or Without Food

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BIBR 1048 MS tablet
Drug: BIBR 1048 MS solution
First Posted Date
2014-06-23
Last Posted Date
2014-06-23
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
6
Registration Number
NCT02170922

Bioavailability of BIBR 963 ZW After 50 mg of BIBR 1048 MS With and Without of Pantoprazole in Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BIBR 1048 MS Capsule D
Drug: BIBR 1048 MS tartaric acid solution
Drug: BIBR 1048 MS Capsule C
Drug: BIBR 1048 MS Capsule A
Drug: BIBR 1048 MS Capsule B
First Posted Date
2014-06-23
Last Posted Date
2014-06-23
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
16
Registration Number
NCT02170896

Relative Bioavailability of Dabigatran and Atorvastatin in Healthy Male and Female Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-06-23
Last Posted Date
2018-08-31
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT02171039

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Phase 1
Completed
Conditions
Hepatic Insufficiency
Interventions
First Posted Date
2014-06-23
Last Posted Date
2014-06-23
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24
Registration Number
NCT02170571

Pharmacokinetic (PK) Assessment of BIBR 1048 in Patients After Primary Elective Total Hip Replacement Surgery

Phase 2
Completed
Conditions
Venous Thromboembolism
Interventions
Drug: BIBR 1048 capsule
First Posted Date
2014-06-23
Last Posted Date
2014-06-23
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
62
Registration Number
NCT02170935

Bioavailability of BIBR 953 ZW After Dose of BIBR 1048 MS

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-06-23
Last Posted Date
2014-06-23
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
30
Registration Number
NCT02170792

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

First Posted Date
2014-06-17
Last Posted Date
2018-07-31
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
2725
Registration Number
NCT02164864
Locations
🇫🇷

CLI du Pont de Chaume, Montauban, France

🇨🇿

Hospital Jihlava, Jihlava, Czechia

🇩🇪

Klinikum Coburg gGmbH, Coburg, Germany

and more 415 locations

Relative Bioavailability of a BI 187004 Tablet Formulation in Comparison With an Oral Solution and the Influence of Food on the Tablet Formulation in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2014-06-11
Last Posted Date
2016-01-27
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
17
Registration Number
NCT02161432
Locations
🇩🇪

1307.3.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy